MAKERSL · Makers Laboratories Ltd · Major Drugs
MAKERSL · Makers Laboratories Ltd · Major Drugs
As of 06 Nov close
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹43 Cr
Revenue YoY
PAT YoY
+240.9%
Operating margin
Revenue, last 5 quarters
P/E (TTM)
P/B
1.8
P/S (TTM)
0.7
Sector P/E
33.6
Dividend yield
0.0%
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| MAKERSL (this stock) | 33.2 | 1.8 | +2.3% | +4.7% | 0.08 | 0.0% |
| Aurobindo Pharma | 24.7 | 2.9 | +10.6% | +9.8% | 0.21 | 0.0% |
| Neuland Laboratories | 60.5 | 11.9 | +18.0% | +21.4% | 13.9 | +0.2% |
| Pfizer | 27.6 | 5.1 | +28.6% | +17.5% | 0.02 | +1.9% |
Promoter
stable
FII
Not available from data source
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
Governance disclosures
AI-generatedNo governance disclosures identified in MAKERSL's filed documents yet.